Dendritic vaccine immunotherapy in pediatric oncology
Supplementum 01/2019 Imunoterapie
MUDr. Peter Múdry, Ph.D.1; doc. RNDr. Lenka Zdražilová Dubská, Ph.D.2
1 Klinika dětské onkologie LF MU a FN Brno
2 Masarykův onkologický ústav, Brno 2 Farmakologický ústav LF MU, Brno
SUMMARY
Immunotherapies with dendritic cell vaccines are studied for two decades in children with high risk tumors. Majority of subjects are at late stage of disease and heavily pretreated with immunosupresive therapies. Despite this, laboratory signs of response in humoral and cellular immunity and clinical benefit rate and objective responses are observed. The comparison between studies is limited due to different inclusion criteria, diseases and designs of vaccine manufacturing and route of administration. Further research will be focused on depletion of T regulatory lymphocytes by either metronomic low dose chemotherapy or concomitant treatment with immune check-point inhibitors. High risk subjects early after induction treatment with tumor response to conventional therapies will be included. The first clinical trial experience of treatment with dendritic cell vaccine in children in Czech Republic is discussed.
KEY WORDS
dendritic vaccine, sarcoma, glioma, neuroblastoma, child
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...